Ciprofloxacin: In Vitro, Experimental, and Clinical Evaluation

Thadepalli, Haragopal; Bansal, Madhu B.; Rao, Bhavani; See, Rosaline; Chuah, See Kean; Marshall, Rosemarie; Dhawan, Vinod K.

doi:10.1093/clinids/10.3.505

Cited by 25 publications

(10 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ciprofloxacin is a new 6-fluoro-7-piperazino-4 quinolone that is highly active against a broad array of microorganisms, including intracellular pathogens such as mycobacteria, brucellae, legionellae, and chlamydiae (11).…”

mentioning

confidence: 99%

Randomized double-blind evaluation of ciprofloxacin and doxycycline for Mediterranean spotted fever

Gudiol

Pallarés

Carratalà

et al. 1989

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Randomized double-blind evaluation of ciprofloxacin and doxycycline for Mediterranean spotted fever

Gudiol

Pallarés

Carratalà

et al. 1989

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Most of the quinolones exhibit an in vitro and in vivo discrepancy in antimicrobial efficacy against B. fragilis, that is, they may show clinical therapeutic efficacy despite the observed in vitro tolerance. For example, in vitro the MIC 90 of B. fragilis to ciprofloxacin was 8 Ìg/ml or more [21], but as a single antibiotic it cured mixed aerobic/ anaerobic infections [12]. This discrepancy could not be explained based on several environmental factors examined [22].…”

Section: Discussionmentioning

confidence: 97%

“…In a previous report, monotherapy with ciprofloxacin was effective in the treatment of acute pelvic infection caused by mixed aerobic/anaerobic bacteria [4]. In the past, ciprofloxacin [20], certain aryl-fluoroquinolones [11,12,15] and, more recently, trovafloxacin [13] Data are given as numbers of specimens yielding B. fragilis/number of animals sampled (mean concentration of CFU/ml). Exp = Experiment.…”

Section: Discussionmentioning

confidence: 99%

“…The mice were treated with moxifloxacin (Bayer, New Haven, Conn., USA), levofloxacin (commercial), clindamycin (com- A mouse received seven times the human dose because of its small body size and faster elimination rates. The dosages of clindamycin and metranidazole selected in this study were based on previously published data [11][12][13][14][15]. Mice that were infected but treated with saline were used as controls.…”

Section: Antibiotic Therapymentioning

confidence: 99%

“…Although IAA are polymicrobially associated with enteric gram-negative bacilli and anaerobes, we chose to use the monomicrobial abscess induced by B. fragilis, to unequivocally establish the efficacy of moxifloxacin against anaerobic infection. Using this animal model, we have previously reported that trovafloxacin and other quinolones are effective in clearing experimentally induced IAA [11][12][13][14][15].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Therapeutic Efficacy of Moxifloxacin, a New Quinolone, in the Treatment of Experimental Intra-Abdominal Abscesses Induced by <i>Bacteroides fragilis </i>in Mice

Thadepalli

Chuah²,

Gollapudi³

2004

Chemotherapy

View full text Add to dashboard Cite

Moxifloxacin, a new quinolone, is effective in vitro against several anaerobic bacteria including Bacteroides fragilis, but its in vivo activity against anaerobic infections is not known. In this study, we evaluated the in vivo activity of moxifloxacin in the treatment of experimentally induced intra-abdominal abscesses (IAA) caused by B. fragilis. For comparison, clindamycin, metronidazole, and levofloxacin were used, and saline for control. Absence of bacteria (sterile) in the abscess pus was required to call it a cure. Mice were intraperitoneally injected with B. fragilis plus sterile rat feces and barium sulfate. Animals were treated with moxifloxacin (40 mg/kg/b.i.d.), clindamycin (75 mg/kg/b.i.d.), levofloxacin (40 mg/kg/b.i.d.) or metronidazole (75 mg/kg/b.i.d.) for 10 days. The cure rate was 12% in controls on saline therapy, 57% on metronidazole, 67% on levofloxacin, 73% on moxifloxacin and 79% on clindamycin. The therapeutic efficacy of moxifloxacin in this B. fragilis infection was not significantly different from that observed with clindamycin. By virtue of its established efficacy on gram-negative aerobic bacteria and the observed in vivo efficacy on B. fragilis, moxifloxacin can be evaluated in the treatment of clinical anaerobic infections.

show abstract

Oral Ciprofloxacin vs Parenteral Cefotaxime in the Treatment of Difficult Skin and Skin Structure Infections

Gentry

Ramírez-Ronda²,

Rodríguez-Noriega³

et al. 1989

Arch Intern Med

View full text Add to dashboard Cite

Ciprofloxacin: In Vitro, Experimental, and Clinical Evaluation

Cited by 25 publications

References 39 publications

Randomized double-blind evaluation of ciprofloxacin and doxycycline for Mediterranean spotted fever

Randomized double-blind evaluation of ciprofloxacin and doxycycline for Mediterranean spotted fever

Therapeutic Efficacy of Moxifloxacin, a New Quinolone, in the Treatment of Experimental Intra-Abdominal Abscesses Induced by <i>Bacteroides fragilis </i>in Mice

Oral Ciprofloxacin vs Parenteral Cefotaxime in the Treatment of Difficult Skin and Skin Structure Infections

Contact Info

Product

Resources

About